A step forward: imaging-based approach to in-stent restenosis

Evan Shlofmitz*, DO

St. Francis Hospital - The Heart Center, Roslyn, NY, USA

In-stent restenosis (ISR) remains a common problem in contemporary practice despite significant advances in interventional tools and techniques¹. ISR is not a binary finding, however, and we have evolved from simply stratifying ISR based on focal or diffuse patterns, to specific patterns based on intravascular imaging appearance including neointimal hyperplasia, calcified or non-calcified neoatherosclerosis and underexpansion^{2,3}. In fact, recognition of the predominant lesion morphology has important treatment implications guiding optimal therapy.

In the present issue of EuroIntervention, Xhepa and colleagues evaluated, in a multicentre, optical coherence tomography (OCT)based registry of lesions treated for in-stent restenosis (ISR), the role of drug-eluting stents (DES) and drug-coated balloons (DCB) based on lesion inhomogeneity⁴.

Article, see page 388

Notably, irrespective of the mechanism of restenosis, event rates were significant, with target lesion revascularisation (TLR) occurring in one quarter of patients, highlighting the importance of identifying improved treatment approaches for this subset of lesions. The authors demonstrated that tailored treatment based on OCT findings may have a favourable impact on clinical outcomes.

The rate of adverse events, particularly TLR, was high irrespective of ISR type or treatment applied. This highlights the importance of preventing ISR in the first place. Underexpansion, which was not the primary focus of the present study, was common and present in the majority of the lesions studied. Stent underexpansion is an entity that is best addressed at the time of initial stent implantation; however, it must first be recognised. Even better is predicting its occurrence by recognising significant calcification and addressing it prior to stent implantation⁵. Until intravascular imaging is the standard of care for percutaneous coronary interventions, stent underexpansion will continue to plague interventional cardiology. Applying a lesion-specific treatment approach with maximally sized stents is critical to minimise future ISR⁶. Prevention of ISR must take precedence and should be considered with each and every stent implanted. We now have the imaging catheters, lesion preparation devices and treatment algorithms readily available to allow us to reduce TLR meaningfully.

*Corresponding author: St. Francis Hospital – The Heart Center, 100 Port Washington Blvd., Suite 105, Roslyn, NY 11576, USA. E-mail: Evan.Shlofmitz@CHSLI.org

DOI: 10.4244/EIJV17I5A61

According to the 2018 European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Guidelines on myocardial revascularisation, there is a Class IIa, level of evidence C recommendation for intravascular imaging to be considered to detect stent-related mechanical problems associated with restenosis7. Perhaps the time has come for intravascular imaging to be more than just considered when treating stent failure. ISR has been the Achilles' heel for interventional cardiology since the introduction of coronary stents. Further work is needed specifically assessing the impact of intravascular imaging in clinical practice on the treatment of ISR. Fundamentally, when encountering any problem, a root cause analysis is a critical step in the pathway to systematically evaluating and overcoming the shortcoming. The same is true when addressing ISR. One cannot treat ISR effectively without understanding the primary mechanism of stent failure, and this cannot be achieved without intravascular imaging. The authors acknowledge a major limitation of the present literature, with most data from randomised trials on restenosis being based on angiography-guided treatment and endpoints. Angiography-based outcomes should no longer be the primary imaging endpoint in trials on ISR. Randomised trials analysing treatment options for ISR, guided by intravascular imaging with intravascular imaging endpoints, are needed. The future of treating ISR is lesion-specific treatment guided by intravascular imaging. The next frontier for coronary interventions in interventional cardiology is not further iterations in stent design, but a change to a patient-centred approach with treatment tailored specifically to the lesion subtype. The future is now, and this can be facilitated by routine and systematic utilisation of intravascular imaging.

Conflict of interest statement

E. Shlofmitz is a consultant for Abbott Vascular, Cardiovascular Systems Inc., Opsens Medical, Philips and Shockwave Medical. He serves on advisory boards for Abbott Vascular and Philips and is on the speaker's bureau for Janssen Pharmaceuticals and Medtronic.

References

1. Moussa ID, Mohananey D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, Waksman R, Teirstein P, Moses JW, Simonton C. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. *J Am Coll Cardiol.* 2020;76: 1521-31.

2. Gonzalo N, Serruys PW, Okamura T, van Beusekom HM, Garcia-Garcia HM, van Soest G, van der Giessen W, Regar E. Optical coherence tomography patterns of stent restenosis. *Am Heart J.* 2009;158:284-93.

3. Shlofmitz E, Iantorno M, Waksman R. Restenosis of Drug-Eluting Stents: A New Classification System Based on Disease Mechanism to Guide Treatment and State-of-the-Art Review. *Circ Cardiovasc Interv.* 2019;12:e007023.

4. Xhepa E, Bresha J, Joner M, Hapfelmeier A, Rivero F, Ndrepepa G, Nano N, Cuesta J, Kufner S, Cassese S, Bastante T, Aytekin A, Rroku A, Garcia-Guimaraes M, Lahmann AL, Pinieck S, Rai H, Fusaro M, Schunkert H, Perez-Vizcayno MJ, Gonzalo N, Alfonso F, Kastrati A. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. *EuroIntervention*. 2021;17:e388-95.

5. Fujino A, Mintz GS, Matsumura M, Lee T, Kim SY, Hoshino M, Usui E, Yonetsu T, Haag ES, Shlofmitz RA, Kakuta T, Maehara A. A new optical coherence tomographybased calcium scoring system to predict stent underexpansion. *EuroIntervention*. 2018;13:e2182-9.

6. Shlofmitz E, Ali ZA, Maehara A, Mintz GS, Shlofmitz R, Jeremias A. Intravascular Imaging-Guided Percutaneous Coronary Intervention: A Universal Approach for Optimization of Stent Implantation. *Circ Cardiovasc Interv.* 2020;13:e008686.

7. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. *EuroIntervention*. 2019;14:1435-534.